Navigation Links
XShares Supports Parkinson's Disease Foundation 50th Anniversary Educational Symposium
Date:10/10/2007

NEW YORK, Oct. 10 /PRNewswire/ -- XShares Advisors LLC, on behalf of the HealthShares(TM) family of ETFs, kicked off a 12-month supporting relationship with the Parkinson's Disease Foundation (PDF), a leading national presence in Parkinson's research, education and public advocacy.

XShares' platinum level support of the PDF 50th Anniversary Educational Symposium, Frontiers of Science and Clinical Advances in Quality of Life, and exclusive support of the symposium webcast, will introduce the HealthShares(TM) family of ETFs and, in particular, the HealthShares(TM) Neuroscience ETF (NYSE: HHN) as an innovative means to invest in companies engaged in Parkinson's research.

"XShares' relationship with the PDF allows us to support an outstanding organization while building awareness of the HealthShares(TM) family of ETFs," said Jeff Feldman, Chairman and Founder of XShares Group LLC. "We believe that those who are personally invested in the PDF's mission-whether as donors, educators, advocates or volunteers-will value the opportunity to invest in a neuroscience portfolio that represents some of the most exciting Parkinson's research taking place in publicly-traded companies."

The two-day symposium is expected to attract 700+ on-site attendees, a webcast audience of thousands and tens of thousands of new and repeat viewers once the webcast is archived on http://www.pdf.org.

"Parkinson's is devastating disease that affects nearly one million Americans," said Robin Elliott, PDF's Executive Director. "We are grateful that HealthShares' support of the Parkinson's Disease Foundation's 50th Anniversary Educational Symposium webcast will enable PDF to reach even more members of the Parkinson's disease community with the information that they need on the most important topics in Parkinson's basic and clinical research today."

About HealthShares(TM)

HealthShares(TM) is a family of 20 Exchange Traded Funds (ETFs), which are organized into therapeutic 'Verticals' and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g., neuroscience, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking. For more information, visit the company's website at http://www.healthsharesinc.com.

About XShares Advisors

XShares Advisors LLC, a subsidiary of XShares Group LLC, is a registered investment advisor that provides investment advisory services to Exchange-Traded Funds. XShares also partners with major institutions and index providers seeking to bring innovative Exchange-Traded Funds to market using its administrative platform. In addition, XShares creates and licenses distinctive intellectual property for its ETFs, developing products that allow for innovative trading strategies and alternative investments for the financial community. For more information, visit the website at http://www.xsharesadvisors.com.

About Parkinson's Disease Foundation

The Parkinson's Disease Foundation (PDF) is a leading national presence in Parkinson's disease research, education and public advocacy. We are working for the nearly one million people in the US living with Parkinson's by funding promising scientific research and supporting people with Parkinson's, their families and caregivers through educational programs and support services.

Since its founding in 1957, PDF has funded over $70 million worth of scientific research in Parkinson's disease, supporting the work of leading scientists throughout the world. An Investor should consider the fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the fund call 800.925.2870 or visit the website http://www.healthsharesinc.com for a prospectus. Please read the prospectus carefully before investing.

-- There are risks involved with investing in ETFs including possible loss of money. HealthShares(TM) are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. Losses from short sales may be unlimited, and losses from purchases on margin may exceed original investment. HealthShares(TM) ETFs are subject to increased risks associated with investing in a specific sector compared to a more diversified investment, as well as unique risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.).

-- The ETFs face additional risks attributable to their investments in small and medium capitalization companies which are subject to higher volatility than larger, more established companies. In addition, they are invested in a limited number of securities and a decline in the value of these investments would cause the fund's overall value to decline to a greater degree than in a less concentrated portfolio.

-- Global or International Funds invest in foreign securities that will be subject to certain risks not associated with domestic securities, such as currency fluctuations, and changes in political and economic conditions.

The prospectus is not an offer to buy or sell the portfolio shares, nor is the fund soliciting an offer to buy its shares in any jurisdiction where the offer or sale is not permitted.

HealthShares(TM) Exchange Traded Funds are distributed by ALPS Distributors, Inc.

XShares Advisors LLC and ALPS Distributors, Inc. are unaffiliated entities.

HSI 315 EXP 9-30-2008

Contact Information

For XShares:

Melissa Kanter

Edelman

212-704-8261

melissa.kanter@edelman.com


'/>"/>
SOURCE HealthShares(TM) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vitamin E supports Female Hearts
2. Injection supports Heart Devices
3. Study supports vegetable diet
4. Study supports century-old cancer theory
5. Google Supports Indians Novel Literacy Drive
6. Actor Anil Kapoor Supports Birth Registration Cause
7. AMA Supports Tax Penalty for Uninsured Americans
8. Church Supports HIV Test Before Marriage
9. EHRVA Supports EHR Product Certification
10. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
11. Bush Supports Restriction to ‘Morning–After’ Pll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... ... March 23, 2017 , ... On ... Dagger Foundation the US Special Operations Command’s Patriot Award. The award was presented ... thanked Task Force Dagger Foundation for its significant and enduring support to the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: